Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Minority Interest (2021 - 2025)

Rani Therapeutics Holdings has reported Minority Interest over the past 5 years, most recently at $8.5 million for Q4 2025.

  • Quarterly results put Minority Interest at $8.5 million for Q4 2025, up 466.42% from a year ago — trailing twelve months through Dec 2025 was $8.5 million (up 466.42% YoY), and the annual figure for FY2025 was $8.5 million, up 466.42%.
  • Minority Interest for Q4 2025 was $8.5 million at Rani Therapeutics Holdings, up from -$4.1 million in the prior quarter.
  • Over the last five years, Minority Interest for RANI hit a ceiling of $80.3 million in Q3 2021 and a floor of -$4.1 million in Q3 2025.
  • Median Minority Interest over the past 5 years was $14.9 million (2023), compared with a mean of $24.5 million.
  • Peak annual rise in Minority Interest hit 466.42% in 2025, while the deepest fall reached 254.92% in 2025.
  • Rani Therapeutics Holdings' Minority Interest stood at $74.2 million in 2021, then crashed by 49.9% to $37.1 million in 2022, then plummeted by 66.14% to $12.6 million in 2023, then tumbled by 88.07% to $1.5 million in 2024, then skyrocketed by 466.42% to $8.5 million in 2025.
  • The last three reported values for Minority Interest were $8.5 million (Q4 2025), -$4.1 million (Q3 2025), and -$3.6 million (Q2 2025) per Business Quant data.